MicroRNA-133a在复发性肝细胞癌中差异表达及临床病理意义  

Expression of microRNA-133a in recurrent hepatocellular carcinoma and its relationship with clinicopathological parameters

作　　者：谷晓媛 陆新元[2] 张为强 GU Xiao-yuan;LU Xin-yuan;ZHANG Wei-qiang(Dept, of Oncology, Shanghai Shibei Hospital of Jing＇an District, Shanghai 200443, China;Dept, of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Militaiy Medical University, Shanghai 200438, China)

机构地区：[1]上海市静安区市北医院肿瘤科,上海200443 [2]第二军医大学东方肝胆外科医院病理科,上海200438

出　　处：《同济大学学报（医学版）》2017年第6期23-26,共4页Journal of Tongji University(Medical Science)

基　　金：国家自然科学基金青年项目(81602603);上海市卫生和计划生育委员会项目(20144Y0047)

摘　　要：目的探讨miR-133a在不同复发时间间隔复发性肝癌中的表达差异,并研究其表达水平与临床病理参数间的关系。方法收集短期复发组及远期复发组病例资料;通过实时荧光定量PCR验证miR-133a在短期复发组及远期复发组表达的差异;统计分析miR-133a表达与临床病理参数间的关系。结果短期复发组的miR-133a相对表达量显著高于远期复发组;miR-133a的表达与年龄、性别、HBs Ag、HBe Ag、血清AFP、总胆红素、白蛋白、ALT、AST、凝血酶原时间、肿瘤数量、肿瘤大小、病理分级、组织学类型、肿瘤位置、肝硬化、肿瘤包膜有无、术后介入治疗无关,而仅与HBV-DNA、微血管浸润、子灶有无、T分期有关。结论 miR-133a可以作为肝癌患者预后的分子标志物,并为患者术后个体化诊治提供理论依据。对肝细胞癌患者进行miR-133a表达水平检测,若表达水平较高,则短期复发风险较高,可在手术基础上积极行术后干预,以改善预后。Objective To investigate the expression of microRNA-133a （miR-133a） in recurrent hepatocellular carcinoma and its relationship with clinicopathological parameters. Methods Clinical and pathological data of 118 patients with hepatocellular carcinoma were enrolled in the study, including 44 cases of short-term recurrence （ 〈2 y） and 74 cases of long-term recurrence （ 〉2 y）. The expression of miR-133 a in liver cancer tissue was detected by real-time fluorescence quantitative PCR. The relationship between miR-133a expression and clinicopathological parameters was analyzed. Results The relative expression of miR-133 a in short-term recurrence group was significantly higher than that in long-term recurrence group. The expression of miR-133a was correlated HBV DNA,microvascular invasion, satellite focus and T stage, but not correlated with age, sex, HBsAg, HBeAg, serum AFP, total bilirubin, albumin, ALT, AST, prothrombin time, number of tumors, tumor size, pathologic stage, histological type, tumor location, liver cirrhosis, tumor capsule, and postoperative interventional therapy. Conclusion The expression of miR-133a is associated with the short-term recurrence, indicating that it can serve as a molecular marker for prognosis of patients with hepatocellular carcinoma.

关 键 词：miR-133a 肝细胞癌 复发 临床病理参数 

分 类 号：R735.7[医药卫生—肿瘤]